Posted by Michael Wonder on 18 Feb 2022
Dizal Pharmaceutical receives U.S. FDA fast track designation for DZD4205 (golidocitinib) for the treatment of refractory or relapsed peripheral T-cell lymphoma
18 February 2022 - Fast track designation proves Dizal's world leading capability of developing potential first-in-class and much needed therapy to cancer patients.
Dizal Pharmaceutical today announced that the U.S. FDA has granted fast track designation to DZD4205 (golidocitinib) for the treatment of patients with refractory or relapsed peripheral T-cell lymphoma.
